more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$71.21 USD

-0.73 (-1.01%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $71.19 -0.02 (-0.03%) 4:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

Bottom 33% (170 out of 252)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio

by Zacks Equity Research Published on July 19,2021

Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.

medical

Base Test Rebound to Drive Quest Diagnostics (DGX) Q2 Earnings

by Zacks Equity Research Published on July 19,2021

Quest Diagnostics' (DGX) second-quarter performance within its non-COVID base business might have registered significant sales rebound.

Why Henry Schein (HSIC) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research Published on July 16,2021

Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

HSICNegative Net Change

Lower COVID-19 Testing Demand to Drag Abbott (ABT) Q2 Earnings

by Zacks Equity Research Published on July 16,2021

Apart from COVIG-19 test related hiccups, Abbott (ABT) is likely to have suffered from significant sales decline within its pediatric nutrition business in Q2.

3 Stocks to Tap the Promising Dental Supplies Industry

by Trina Mukherjee Published on July 15,2021

Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical-Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.

medical

Is Henry Schein (HSIC) Stock Undervalued Right Now?

by Zacks Equity Research Published on July 14,2021

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

HSICNegative Net Change

Stryker (SYK) Unveils Tornier Shoulder Arthroplasty Portfolio

by Zacks Equity Research Published on July 14,2021

Stryker (SYK) introduces new Tornier shoulder arthroplasty portfolio enabling the company to strengthen its position in the shoulder market.

medical

Here's Why You Should Retain Change Healthcare (CHNG) Stock

by Zacks Equity Research Published on July 14,2021

Change Healthcare (CHNG) continues to benefit from robust payment accuracy business. However, intense competition remains a woe.

medical

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research Published on July 13,2021

Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System.

medical

What Makes Align Technology (ALGN) a Solid Choice Right Now?

by Zacks Equity Research Published on July 09,2021

Strong performance and latest innovations in the Invisalign and iTero family are driving the top line for Align Technology (ALGN).

medical

Dental Space Gains Momentum in 2021: 4 Stocks to Invest in

by Debanjana Dey Published on July 08,2021

Dental stocks like Henry Schein (HSIC), Align Technology (ALGN), Straumann Holding (SAUHF) and DENTSPLY SIRONA (XRAY) are expected to continue their run over the next few months.

medical

Bet on 4 Low-Beta MedTech Stocks to Ride the Choppy Market

by Riya Anand Published on July 06,2021

Stocks like Henry Schein (HSIC), BellRing Brands (BRBR), Harrow Health (HROW) and West Pharmaceuticals Services (WST) are solid low-beta picks with strong fundamentals.

medical

HSIC vs. COO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research Published on July 05,2021

HSIC vs. COO: Which Stock Is the Better Value Option?

Top Ranked Growth Stocks to Buy for July 1st

by Zacks Equity Research Published on July 01,2021

VALE, HCCI, X, and HSIC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 1, 2021

3 Reasons to Add AMN Healthcare (AMN) to Your Portfolio

by Zacks Equity Research Published on July 01,2021

Investors continue to be optimistic about AMN Healthcare (AMN) due to its broad array of services and strength in staffing service.

medical

3 Best MedTech Growth Stocks to Bet On in 2021 Amid Pandemic

by Trina Mukherjee Published on July 01,2021

Grab these three top stocks, EYE, WST and HSIC, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.